A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL

Abstract

This observational study included 21 patients at remarkably high risk of ovarian hyperstimulation syndrome (OHSS), characterized by more than 30 follicles measuring ≥11 mm in diameter on trigger day and/or pre-trigger peak estradiol exceeding 10 000 pg/mL, which was also the feature of women with established severe early OHSS followed by gonadotrophin-releasing hormone agonist (GnRHa) trigger and freeze-all policy that previously have been reported. All patients received a second dose of GnRHa 12 h after the first GnRHa trigger combined with administration of GnRH antagonist at 0.25 mg/day for a period of 3 days from the day of oocyte retrieval onwards. The in vitro fertilization (IVF) outcomes may be preferable compared with a bolus of GnRHa trigger and none of the included patients developed moderate-to-severe OHSS. Moreover, patients’ symptoms, reproductive hormone levels and ultrasound findings were improved significantly. This new strategy seems to be efficacious and could be a further supplement of GnRHa trigger with or without applying freeze-all strategy to completely prevent early-onset moderate to severe OHSS, especially for the patients characterized by ≤30 follicles measuring ≥11 mm in diameter on trigger day and/or pre-trigger peak estradiol exceeding 10 000 pg/mL. Further studies should be performed to compare this regimen with conventional methods of OHSS prevention.

Keywords

in-vitro fertilization / ovarian hyperstimulation syndrome / GnRH agonist / GnRH antagonist / freeze-all

References

[1] KawwassJF, KissinDM, KulkarniAD, et al.. Safety of assisted reproductive technology in the United States, 2000–2011. JAMA, 2015, 313(1): 88-90

[2] StewardRG, LanL, ShahAA, et al.. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256, 381 in vitro fertilization cycles. Fertil Steril, 2014, 101(4): 967-973

[3] BrinsdenPR, WadaI, TanSL, et al.. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol, 1995, 102(10): 767-772

[4] Pfeifer S BSDD.. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril, 2016, 106(7): 1634-1647

[5] AbbaraA, ClarkeS, IslamR, et al.. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod, 2017, 32(9): 1915-1924

[6] HumaidanP, BungumL, BungumM, et al.. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online, 2005, 11(6): 679-684

[7] LainasGT, KolibianakisEM, SfontourisIA, et al.. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrin, 2012, 10: 69

[8] MaisV, KazerRR, CetelNS, et al.. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. J Clin Endocrinol Metab, 1986, 62(6): 1250-1255

[9] LainasGT, KolibianakisEM, SfontourisIA, et al.. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG, 2014, 121(7): 848-855

[10] KrasnowJS, BergaSL, GuzickDS, et al.. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril, 1996, 65(3): 552-555

[11] SoaresSR, GomezR, SimonC, et al.. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update, 2008, 14(4): 321-333

[12] Bonilla-MusolesFM, RagaF, CastilloJC, et al.. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol, 2009, 36(2): 78-81

[13] LainasTG, SfontourisIA, ZorzovilisIZ, et al.. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18(1): 15-20

[14] LainasTG, SfontourisIA, ZorzovilisIZ, et al.. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online, 2007, 15(4): 408-412

[15] AsimakopoulosB, NikolettosN, NehlsB, et al.. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril, 2006, 86(3): 636-641

[16] DevroeyP, PolyzosNP, BlockeelC. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod, 2011, 26(10): 2593-2597

[17] AtkinsonP, KochJ, LedgerWL. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: A retrospective study of OHSS risk and pregnancy rates. Au N Z J Obstet Gynaecol, 2014, 54(6): 581-585

[18] KaracanM, ErdemE, UstaA, et al.. Gonadotropin-releasing hormone agonist triggering with concomitant administration of low doses of human chorionic gonadotropin or a freeze-all strategy in high responders. Saudi Med J, 2017, 38(6): 586-591

[19] ItskovitzJ, BoldesR, LevronJ, et al.. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril, 1991, 56(2): 213-220

[20] LanzoneA, FulghesuAM, ApaR, et al.. LH surge induction by GnRH agonist at the time of ovulation. Gynecol Endocrinol, 1989, 3(3): 213-220

[21] ChenSL, YeDS, ChenX, et al.. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod, 2012, 27(5): 1351-1356

[22] YoussefMA, Van der VeenF, Al-InanyHG, et al.. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev, 2014, 10: D8046

[23] ChandrasekherYA, BrennerRM, MolsknessTA, et al.. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. II. Progesterone receptor expression in luteinizinggranulosa cells. J Clin Endocrinol Metab, 1991, 73(3): 584-589

[24] Zelinski-WootenMB, LanzendorfSE, WolfDP, et al.. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function. J Clin Endocrinol Metab, 1991, 73(3): 577-583

[25] CerrilloM, PachecoA, RodríguezS, et al.. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril, 2011, 95(8): 2517-2519

[26] FatemiHM, Popovic-TodorovicB, HumaidanP, et al.. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril, 2014, 101(4): 1008-1011

[27] GurbuzAS, GodeF, OzcimenN, et al.. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online, 2014, 29(5): 541-544

[28] MahajanN, GuptaS, SharmaS, et al.. Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis. J Hum Reprod Sci, 2015, 8(4): 234-238

[29] GriesingerG, SchultzL, BauerT, et al.. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril, 2011, 95(6): 2029-2033 2031–2033

[30] LingLP, PhoonJW, LauMS, et al.. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy’. Reprod Biomed Online, 2014, 29(3): 392-394

[31] Santos-RibeiroS, PolyzosNP, StouffsK, et al.. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition. J Assist Reprod Genet, 2015, 32(7): 1063-1068

[32] HernándezER, Gómez-PalomaresJL, RicciarelliE. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril, 2009, 91(4): 1358-1361

[33] AcevedoB, Gomez-PalomaresJL, RicciarelliE, et al.. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril, 2006, 86(6): 1682-1687

[34] HumaidanP, QuartaroloJ, PapanikolaouEG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2): 389-400

[35] PauE, Alonso-MurielI, GomezR, et al.. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod, 2006, 21(6): 1453-1460

[36] Zelinski-WootenMB, HutchisonJS, ChandrasekherYA, et al.. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles. J Clin Endocrinol Metab, 1992, 75(2): 502-507

[37] KolS, BreyzmanT, SegalL, et al.. ‘Luteal coasting’ after GnRH agonist trigger — individualized, HCG-based, progesterone-free luteal support in ‘high responders’: a case series. Reprod Biomed Online, 2015, 31(6): 747-751

[38] WhelanJR, VlahosNF. The ovarian hyperstimulation syndrome. Fertil Steril, 2000, 73(5): 883-896

[39] EftekharM, MirajS, MortazavifarZ. The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS. Int J Reprod Biomed (Yazd), 2016, 14(8): 507-510

[40] LainasGT, KolibianakisEM, SfontourisIA, et al.. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod, 2013, 28(7): 1929-1942

[41] Siler-KhodrTM, KhodrGS, RhodeJ, et al.. Gestational age-related inhibition of placental hCG, alpha hCG and steroid hormone release in vitro by a GnRH antagonist. Placenta, 1987, 8(1): 1-14

[42] TugN, UsluU, CumbulA, et al.. Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy. Eur J Obstet Gynecol Reprod Biol, 2011, 155(2): 166-170

[43] VirolainenJV, LoveRJ, TastA, et al.. Effect of a gonadotrophin-releasing hormone antagonist on luteinising hormone secretion and early pregnancy in gilts. Reprod Fertil Dev, 2003, 15(7–8): 451-459

[44] KolibianakisEM, Schultze-MosgauA, SchroerA, et al.. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod, 2005, 20(10): 2887-2892

[45] EngmannL, BenadivaC, HumaidanP. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod Biomed Online, 2016, 32(3): 274-285